Change for Life Wellness & Aesthetics
- PRP Therapy
- Migraine Treatment
- Hormone Replacement Therapy (HRT)
- Stem Cell Therapy
Washington, DC
Stem Cell Therapy clinics in Washington
Washington supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through MedStar Georgetown, George Washington University Hospital, and Johns Hopkins' DC campuses, and stem cell practice in the area spans Foggy Bottom, Dupont Circle, and Chevy Chase. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Washington DC regulates physician practice through the District of Columbia Board of Medicine. Federal 21 CFR Part 1271 rules apply directly. The district's proximity to FDA headquarters and NIH creates heightened regulatory visibility. The 8 Washington clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and DC Board of Medicine licensure checks.
West End Regenerative Medicine
- PRP Therapy
- Acne Treatment
- Erectile Dysfunction (ED) Treatment
- Stem Cell Therapy
Regulatory context
A note on DC's stem cell therapy rules.
Cellular therapy in the District of Columbia is governed by 21 CFR Part 1271. Minimally manipulated HCT/Ps for homologous use fall under Section 361 and are exempt from premarket approval. Products that are more than minimally manipulated, used non-homologously, or combined with another article fall under Section 351 and require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in the District for orthopedic, neurologic, or longevity indications are Section 351 biologics that lack FDA approval. The District is also subject to FDA inspections and direct federal enforcement.
-
District of Columbia Health Occupations Revision Act, DC Code Title 3, Chapter 12
Establishes physician licensure under the DC Board of Medicine and disciplinary authority over regenerative medicine practitioners. -
DC Pharmacy Act, DC Code Title 47, Chapter 28
Regulates compounding pharmacies operating within the District in alignment with federal 503A and 503B standards. -
DC Consumer Protection Procedures Act, DC Code Title 28, Chapter 39
Empowers the DC Attorney General to pursue deceptive trade practice claims against providers making unsupported clinical claims.
The FDA has corresponded with DC area providers offering stem cell and exosome therapies, and federal enforcement applies directly without the intermediation of a state authority. The DC Board of Medicine has authority to discipline physicians for unprofessional conduct, including misleading advertising of regenerative procedures. The DC Office of the Attorney General has used the Consumer Protection Procedures Act to pursue deceptive health claims. Because the District is small in geographic terms, many DC patients receive cellular therapy in nearby Maryland or Virginia, where state-specific rules also apply.